Skip to main content
Top
Published in: Netherlands Heart Journal 4/2016

Open Access 01-04-2016 | Editor’s Comment

Heart failure with preserved ejection fraction: current status and challenges for the future

Authors: J. van der Velden, E. E. van der Wall, W. J. Paulus

Published in: Netherlands Heart Journal | Issue 4/2016

Login to get access

Excerpt

Over the past two decades it has become evident that more than 50 % of all heart failure patients suffer of heart failure with preserved left ventricular (LV) ejection fraction (HFpEF), previously called diastolic heart failure because of important involvement of diastolic LV dysfunction. The advances and current status of HFpEF research are described in this special focus issue of the Netherlands Heart Journal. HFpEF is the most common heart failure phenotype in ageing societies, highly prevalent in elderly women and frequently accompanied by comorbidities which result from a detrimental lifestyle, such as obesity, metabolic syndrome, type 2 diabetes mellitus and salt-sensitive arterial hypertension [1]. Despite modern heart failure therapy, the prognosis of HFpEF has not improved over the last decades. By 2020, the prevalence of HFpEF is projected to exceed 8 % of persons older than 65 years of age and because of the current pandemic of obesity, the prevalence of HFpEF in persons younger than 65 years of age is expected to rise exponentially. …
Literature
1.
go back to reference Heerebeek L van, Paulus WJ. Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0810-1. Heerebeek L van, Paulus WJ. Understanding heart failure with preserved ejection fraction: where are we today? Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0810-1.
2.
go back to reference Franssen C, Miqueo AG. Role of titin and extracellular matrix remodeling in heart failure with preserved ejection fraction. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0812-z. Franssen C, Miqueo AG. Role of titin and extracellular matrix remodeling in heart failure with preserved ejection fraction. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0812-z.
3.
go back to reference Boonman-de Winter LJM, Cramer MJ, Hoes AW, Rutten FH. Uncovering heart failure with preserved ejection fraction in patients with type 2 diabetes in primary care: time for a change. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0809-7. Boonman-de Winter LJM, Cramer MJ, Hoes AW, Rutten FH. Uncovering heart failure with preserved ejection fraction in patients with type 2 diabetes in primary care: time for a change. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0809-7.
4.
go back to reference Huis in ’t Veld AE, Man FS de, Rossum AC van, Handoko ML. How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0811-0. Huis in ’t Veld AE, Man FS de, Rossum AC van, Handoko ML. How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0811-0.
5.
go back to reference Meijers WC, Velde AR van der, Boer RA de. Biomarkers in heart failure with preserved ejection fraction. Neth Heart J. 2016;24. Meijers WC, Velde AR van der, Boer RA de. Biomarkers in heart failure with preserved ejection fraction. Neth Heart J. 2016;24.
6.
go back to reference Meijers WC, Hoekstra T, Jaarsma T, Veldhuisen DJ van, Boer RA de. Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0817-7. Meijers WC, Hoekstra T, Jaarsma T, Veldhuisen DJ van, Boer RA de. Patients with heart failure with preserved ejection fraction and low levels of natriuretic peptides. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0817-7.
7.
go back to reference Kovács A, Alogna A, Post H, Hamdani N. Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0814-x. Kovács A, Alogna A, Post H, Hamdani N. Is enhancing cGMP-PKG signalling a promising therapeutic target for heart failure with preserved ejection fraction? Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0814-x.
8.
go back to reference Conceição G, Heinonen I, Lourenço AP, Duncker DJ, Falcão-Pires I. Animal models of heart failure with preserved ejection fraction. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0815-9. Conceição G, Heinonen I, Lourenço AP, Duncker DJ, Falcão-Pires I. Animal models of heart failure with preserved ejection fraction. Neth Heart J. 2016;24.DOI: 10.1007/s12471-016-0815-9.
Metadata
Title
Heart failure with preserved ejection fraction: current status and challenges for the future
Authors
J. van der Velden
E. E. van der Wall
W. J. Paulus
Publication date
01-04-2016
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 4/2016
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-016-0808-8

Other articles of this Issue 4/2016

Netherlands Heart Journal 4/2016 Go to the issue